GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Xcorporeal Inc (GREY:XCRP) » Definitions » EPS (Diluted)

Xcorporeal (Xcorporeal) EPS (Diluted) : $-0.18 (TTM As of Sep. 2009)


View and export this data going back to . Start your Free Trial

What is Xcorporeal EPS (Diluted)?

Xcorporeal's Earnings per Share (Diluted) for the three months ended in Sep. 2009 was $-0.10. Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2009 was $-0.18.

Xcorporeal's EPS (Basic) for the three months ended in Sep. 2009 was $-0.10. Its EPS (Basic) for the trailing twelve months (TTM) ended in Sep. 2009 was $-0.18.

Xcorporeal's EPS without NRI for the three months ended in Sep. 2009 was $-0.10. Its EPS without NRI for the trailing twelve months (TTM) ended in Sep. 2009 was $-0.54.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.


Xcorporeal EPS (Diluted) Historical Data

The historical data trend for Xcorporeal's EPS (Diluted) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Xcorporeal EPS (Diluted) Chart

Xcorporeal Annual Data
Trend Feb99 Feb00 Dec01 Dec02 Dec03 Dec04 Dec05 Dec06 Dec07 Dec08
EPS (Diluted)
Get a 7-Day Free Trial Premium Member Only Premium Member Only -3.36 -0.56 -0.67 -1.20 -1.57

Xcorporeal Quarterly Data
Dec04 Mar05 Jun05 Sep05 Dec05 Mar06 Jun06 Sep06 Dec06 Mar07 Jun07 Sep07 Dec07 Mar08 Jun08 Sep08 Dec08 Mar09 Jun09 Sep09
EPS (Diluted) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.76 - -0.01 -0.07 -0.10

Competitive Comparison of Xcorporeal's EPS (Diluted)

For the Medical Devices subindustry, Xcorporeal's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Xcorporeal's PE Ratio Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Xcorporeal's PE Ratio distribution charts can be found below:

* The bar in red indicates where Xcorporeal's PE Ratio falls into.



Xcorporeal EPS (Diluted) Calculation

EPS (Diluted) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Diluted EPS takes into account all of the outstanding dilutive securities that could potentially be exercised (such as stock options and convertible preferred stock) and shows how such an action would impact earnings per share.

Xcorporeal's Diluted EPS for the fiscal year that ended in Dec. 2008 is calculated as

Diluted EPS (A: Dec. 2008 ) = (Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(-22.987-0)/14.604
=-1.57

Xcorporeal's Diluted EPS for the quarter that ended in Sep. 2009 is calculated as

Diluted EPS (Q: Sep. 2009 )=(Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(-1.541-0)/14.759
=-0.10

EPS (Diluted) for the trailing twelve months (TTM) ended in Sep. 2009 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.18

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Xcorporeal  (GREY:XCRP) EPS (Diluted) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Xcorporeal EPS (Diluted) Related Terms

Thank you for viewing the detailed overview of Xcorporeal's EPS (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.


Xcorporeal (Xcorporeal) Business Description

Traded in Other Exchanges
N/A
Address
80 Empire Drive, Lake Forest, CA, USA, 92630
Website
Xcorporeal Inc is a medical device company, developing an innovative extra-corporeal platform technology to be used in devices to replace the function of various human organs.
Executives
Kelly J. Mccrann director, officer: Chairman and CEO 11150 SANTA MONICA BLVD #1500, LOS ANGELES CA 90025
Daniel S Goldberger officer: Chief Executive Officer 24 CARPENTER ROAD, CHESTER NY 10918
Marc G Cummins director C/O PRIME LOGIC CAPITAL, LLC, 135 EAST 57TH STREET, 11TH FLOOR, NEW YORK NY 10022
Prime Logic Capital, Llc 10 percent owner 135 EAST 57TH STREET, 11TH FLOOR, NEW YORK NY 10022
Robert Weinstein officer: Chief Financial Officer 3960 HOWARD HUGHES PARKWAY, SUITE 500, LAS VEGAS NV 89169
Terren S Peizer director, 10 percent owner, officer: Executive Chairman 11111 SANTA MONICABLVD STE.500, LOS ANGELES CA 90025
Jay Wolf director 981 LINDA FLORA DRIVE, LOS ANGELES, CA 90049
Herve De Kergrohen director 22 CHEMIN DU NANTET, COLLONGE-BELLERIVE V8 CH1245
Nicholas Sheridan Lewin director 3 WEST 57TH ST., 8TH FLOOR, NEW YORK NY 10019
Lawrence Lacerte 10 percent owner C/O TERAGLOBAL COMMUNICATIONS CORP, 9171 TOWNE CENTRE DRIVE SUITE 600, SAN DIEGO CA 92122

Xcorporeal (Xcorporeal) Headlines

No Headlines